SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Arte... (G at one year in these same patient grou...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

Date:3/28/2009

G at one year in these same patient groups supports PCI as a rational alternative treatment option for these patients."

SYNTAX is the first randomized, controlled clinical trial to compare PCI using the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System to CABG in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). According to published guidelines, these patients are traditionally treated with CABG, and they have been excluded from most prior drug-eluting stent clinical trials. The goal of the SYNTAX trial is to explore whether it is safe and effective to treat some or all of these 'surgical' patients with PCI using the TAXUS Express2 stent.

The cost-effectiveness analysis compared the relative benefits in overall quality of life to the relative U.S. health care costs, for both PCI and CABG. In those patients with low or moderate lesion complexity, PCI was favored, providing more quality-adjusted life years and lower net medical costs than CABG. For patients with the most complex disease -- and in whom the increase in repeat revascularization for PCI versus CABG was greatest -- CABG provided slightly more quality-adjusted life years, with no significant difference in net medical costs at one year.

The results showed that both PCI and CABG demonstrated equivalent rates of "substantial improvement" in angina relief as compared to baseline at one, six and 12 months (57.6% PCI v. 58.3% CABG at 12 months) (p=statistically insignificant). The number of patients who reported being angina free was comparable for PCI and CABG at one month (64.4% v. 61.6%) and six months (68.5% v. 72.0%) (p=statistically insignificant for both), but was higher in the CABG group at 12 months (71.6% v. 76.3%) (p=0.05).

In addition, the study showed that total medical costs were $5,693 lower for PCI than for CABG for the initial hospitalization (
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
2. SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
3. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
4. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
5. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
6. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
7. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
10. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
11. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results

Post Your Comments:

Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2 Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2 For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3 Eliminate the Blues with Color Therapy 54599 1 Eliminate the Blues with Color Therapy 54599 2 Eliminate the Blues with Color Therapy 54599 3 New biofactories produce rare healing substances in the endangered Devils claw plant 54597 1 New biofactories produce rare healing substances in the endangered Devils claw plant 54597 2 New biofactories produce rare healing substances in the endangered Devils claw plant 54597 3 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 1 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 2 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 3 Heroes of Chemistry for saving teeth clean water new high blood pressure drug 54594 4

[0] Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day [0] For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain

Other Medicine Technology:Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 2 Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 3 AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin 2

Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin

[0] The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website [1] Winner Medical Reports Fourth Quarter and Fiscal 2009 Results [0] Patriot Scientific Corporation Announces New Director [1] Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas [1] Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure

Other Medicine News:Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 2 Health News:Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility 3 Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 2 Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 3 Health News:Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis 4 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6 Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7 Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 2 Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 3 Health News:Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results 4 Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 2 Health News:Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention 3

Medivation to Present at Cowen and Company's 28th Annual Health Care Conference Agito Networks Wins the 2008 VON Magazine Innovator Award for Enterprise Mobility Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results Hope In Action: Policymakers and Artists Promote Youth and Latino Suicide Prevention

Medicine Products:

Encephalitis Antibodies, IgG Electrophoresis, Protein, Serum with Reflex to Immunofixation Electrophoresis, Serum Electrolytes, Serum or Plasma Elavil (Amitriptyline/Nortriptyline)

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Arte...(G at one year in these same patient grou...),Health